Phase II single-arm trial of safety, antitumor activity, and pharmacokinetics of tusamitamab ravtansine (SAR408701) plus ramucirumab in CEACAM5-positive, metastatic, non-squamous, non-small cell lung cancer progressing on platinum-based chemotherapy and immunotherapy

被引：2
|
作者：
Cho, B. C. [1 ]
Aguado de la Rosa, C. [2 ]
Vila, L. [3 ]
Isla, D. [4 ]
Oliveira, J. [5 ]
de Castro Carpeno, J. [6 ]
Tomova, A. [7 ]
Kim, T. M. [8 ]
Blasco Cordellat, A. [9 ]
Bauchet, A-L. [10 ]
Soufflet, C. [11 ]
Bensfia, S. [12 ]
Dy, G. [13 ]
机构：
[1] Yonsei Univ, Yonsei Canc Ctr, Coll Med, Seoul, South Korea
[2] Hosp Clin San Carlos, Madrid, Spain
[3] Parc Tauli Hosp Univ, Barcelona, Spain
[4] Hosp Clin Lozano Blesa, Zaragoza, Spain
[5] Inst Portugues Oncol Porto Francisco Gentil EPE, Porto, Portugal
[6] Hosp Univ La Paz, Madrid, Spain
[7] Complex Oncol Ctr Plovdiv, Plovdiv, Bulgaria
[8] Seoul Natl Univ Hosp, Seoul, South Korea
[9] Hosp Univ Valencia, Valencia, Spain
[10] Sanofi, Chilly Mazarin, France
[11] Sanofi, Boulogne, France
[12] Sanofi, Cambridge, MA USA
[13] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1965
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364TiP
引用
收藏
页码：S1034 / S1035
页数：2
相关论文
共 50 条
  • [1] Open-label, phase II study of tusamitamab ravtansine (SAR408701) in combination with pembrolizumab and with pembrolizumab plus platinum-based chemotherapy plus /- pemetrexed in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05)
    Paz-Ares, L.
    Parakh, S.
    Park, J.
    Rojas, C.
    Orlandi, F.
    Veillon, R.
    Isambert, N.
    Nagy, T.
    Muller, V.
    Medgyasszay, B.
    Rodriguez-Abreu, D.
    Fernandez, A.
    Puaud, A.
    Bensfia, S.
    Yang, N.
    Spira, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S65 - S66
  • [2] Biomarker analysis from phase I/II study of tusamitamab ravtansine (SAR408701) in patients with advanced non-small cell lung cancer (NSCLC)
    Gazzah, A.
    Lee, J. S.
    Wang, E.
    Ternes, N.
    Wang, H.
    Boitier, E.
    Lartigau, A.
    Chadjaa, M.
    Dib, C.
    Muzard, G.
    Valence, S.
    Remaury, A.
    Palu, C. C.
    Bauchet, A-L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S81 - S81
  • [3] Phase III trial comparing antibody-drug conjugate (ADC) SAR408701 with docetaxel in patients with metastatic non-squamous non-small cell lung cancer (NSQ NSCLC) failing chemotherapy and immunotherapy.
    Johnson, Melissa Lynne
    Chadjaa, Mustapha
    Yoruk, Semra
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) tumor expression in a phase I/II study of tusamitamab ravtansine (SAR408701) in patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Scoazec, J-Y.
    Bauchet, A-L.
    Adam, J.
    Rochaix, P.
    MacGrogan, G.
    Kim, J. E.
    Nuciforo, P.
    Lopez-Rios, F.
    Frisman, D.
    Cesarone, G.
    Bernstein, S.
    Lee, J.
    Henry, C.
    Ozoux, M-L.
    Lefebvre, A-M.
    ANNALS OF ONCOLOGY, 2021, 32 : S1011 - S1011
  • [5] Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
    Ricordel, Charles
    Barlesi, Fabrice
    Cousin, Sophie
    Cho, Byoung Chul
    Calvo, Emiliano
    Kim, Tae Min
    Helissey, Carole
    Kim, Jin-Soo
    Vieito, Maria
    Boni, Valentina
    Ghiringhelli, Francois
    Chadjaa, Mustapha
    Masson, Nina
    Soufflet, Christine
    Gazzah, Anas
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
    Lim, Sun Min
    Peters, Solange
    Granados, Ana Laura Ortega
    Pinto, Gustavo dix Junqueira
    Fuentes, Christian Sebastian
    Lo Russo, Giuseppe
    Schenker, Michael
    Ahn, Jin Seok
    Reck, Martin
    Szijgyarto, Zsolt
    Huseinovic, Neda
    Zografos, Eleftherios
    Buss, Elena
    Stjepanovic, Neda
    ODonnell, Sean
    de Marinis, Filippo
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [7] Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial
    Sun Min Lim
    Solange Peters
    Ana Laura Ortega Granados
    Gustavo dix Junqueira Pinto
    Christian Sebastián Fuentes
    Giuseppe Lo Russo
    Michael Schenker
    Jin Seok Ahn
    Martin Reck
    Zsolt Szijgyarto
    Neda Huseinovic
    Eleftherios Zografos
    Elena Buss
    Neda Stjepanovic
    Sean O’Donnell
    Filippo de Marinis
    Nature Communications, 14
  • [8] A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer
    Yamada, Kazuhiko
    Ichiki, Masao
    Takahashi, Kazuhisa
    Hisamatsu, Yasushi
    Takeoka, Hiroaki
    Azuma, Koichi
    Shukuya, Takehito
    Nishikawa, Kazuo
    Tokito, Takaaki
    Ishii, Hidenobu
    Hoshino, Tomoaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 501 - 507
  • [9] A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer
    Kazuhiko Yamada
    Masao Ichiki
    Kazuhisa Takahashi
    Yasushi Hisamatsu
    Hiroaki Takeoka
    Koichi Azuma
    Takehito Shukuya
    Kazuo Nishikawa
    Takaaki Tokito
    Hidenobu Ishii
    Tomoaki Hoshino
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 501 - 507
  • [10] Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5).
    Gazzah, Anas
    Ricordel, Charles
    Cousin, Sophie
    Cho, Byoung Chul
    Calvo, Emiliano
    Kim, Tae Min
    Helissey, Carole
    Kim, Jin-Soo
    Vieito, Maria
    Boni, Valentina
    Chadjaa, Mustapha
    Hospitel, Marie
    Yoruk, Semra
    Barlesi, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345